Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 6/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | DPYD | Q12882 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | C1R | P00736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002554 | 0.77 | MEN1 (0.48) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL17362093 | 0.77 | ACLY (0.42) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL7909779 | 0.75 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL1000301 | 0.75 | DAO (0.50) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL574325 | 0.75 | TTK (0.44) | PKMMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL6986501 | 0.75 | DAO (0.40) | PKMMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL28579313 | 0.73 | LMNA (0.33) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL25651305 | 0.72 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL9730796 | 0.72 | MEN1 (0.38) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL13893571 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PKM 2159/4885MEN1 562/4885KMT2A 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.